Proteus
Digital Health completes $62.5 Million financing. Proceeds to advance
development of digital medicine products.
Full
press release follows.
SOURCE:
Proteus Digital Health
REDWOOD
CITY, Calif.--(BUSINESS WIRE)—May 1,
2013, Proteus Digital Health, Inc., announced today that the company has
completed a second closing of its Series F financing, raising $62.5 million in
total. New corporate investor Oracle joins Otsuka, Novartis, Sino Portfolio and
others in this funding round.
“By
embedding Proteus technology into established, market leading products &
services we are changing healthcare and empowering patients, physicians and
researchers with digital technology.”
Proteus
Digital Health is working to create a new category of products, services and
data systems that have the potential to significantly improve the effectiveness
of existing pharmaceutical treatments, leading to fundamentally new care
paradigms. Called Digital Medicines, these new pharmaceuticals will contain a tiny
sensor that can communicate, via a digital health feedback system, vital
information about an individual’s medication-taking behavior and how their body
is responding.
“The
commitment of our strategic partners helps us to accelerate our mission,” said
Andrew Thompson, CEO of Proteus. “By embedding Proteus technology into
established, market leading products & services we are changing healthcare
and empowering patients, physicians and researchers with digital technology.”
About
Proteus Digital Health
Proteus
Digital Health is pioneering a new category of products, services and data
systems based on ingestible sensing. Its core technology—the digital health
feedback system—provides an unprecedented view into an individual’s personal
health choices and physiologic response, allowing patients to better manage
their health and more effectively collaborate with caregivers and clinicians
while enabling new information-based business models. Proteus has received a CE
mark in Europe and FDA market clearance in the U.S. for its wearable and
ingestible sensor devices. Headquartered in Redwood City, Calif., Proteus
is privately held and funded by Carlyle, Essex Woodlands, Kaiser Permanente,
Medtronic, Novartis, Otsuka, Oracle, ON Semiconductor and other investors. For more
information please visit proteusdigitalhealth.com.
Trademark
Oracle
and Java are registered trademarks of Oracle and/or its affiliates. Other names
may be trademarks of their respective owners.
Contacts
Proteus
Digital Health, Inc.
Robin Suchan, 415-946-1055
rsuchan@wcgworld.com
No comments:
Post a Comment